文献速递类风湿关节炎

柳氮磺吡啶对类风湿关节炎患者耶氏肺孢子菌肺炎的预防作用:一项巢式病例对照研究

Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in patients with rheumatoid arthritis: A nested case-control study.
PubMed 文献 · Semin Arthritis Rheum · 2018-06-13

本研究利用日本全国多中心类风湿关节炎数据库2005至2014年数据,采用巢式病例对照设计,比较60例耶氏肺孢子菌肺炎(PJP)病例与356例未匹配对照及337例匹配对照。结果显示,使用柳氮磺吡啶与PJP风险降低相关(未匹配调整OR 0.18,95%CI 0.00-0.92;匹配OR 0.08,95%CI 0.00-0.36)。作者结论认为柳氮磺吡啶对PJP有预防作用,但结果有待未来前瞻性研究确认。

要点

  • 使用柳氮磺吡啶与PJP风险降低相关,未匹配调整OR 0.18(95%CI 0.00-0.92),匹配OR 0.08(95%CI 0.00-0.36)。
  • 未使用柳氮磺吡啶者中,肺部疾病、糖皮质激素、甲氨蝶呤和TNF抑制剂与PJP风险升高相关。
  • 作者结论认为柳氮磺吡啶对PJP有预防作用,但结果有待未来前瞻性研究确认。

核心结论

  • 这项巢式病例对照研究显示柳氮磺吡啶对PJP具有预防作用,但结果有待未来前瞻性研究确认。

研究设计与样本

  • 利用日本全国多中心类风湿关节炎数据库提取2005年至2014年数据,采用巢式病例对照设计。
  • 从18668名参与者中选出60例PJP病例、356例未匹配对照和337例按年龄、性别、糖皮质激素、甲氨蝶呤、他克莫司剂量及生物改善病情抗风湿药使用情况匹配的对照。
  • 采用精确法和标准条件logistic回归估计PJP与柳氮磺吡啶使用及其他临床因素的比值比。

主要发现

  • 所有PJP病例在发病前均未使用柳氮磺吡啶。
  • 病例与未匹配对照比较,使用柳氮磺吡啶与PJP风险降低相关(调整OR 0.18,95%CI 0.00-0.92)。
  • 病例与匹配对照比较,使用柳氮磺吡啶与PJP风险降低相关(OR 0.08,95%CI 0.00-0.36)。
  • 在未使用柳氮磺吡啶的病例与未匹配对照分析中,肺部疾病(OR 3.88,95%CI 1.89-7.95)、使用糖皮质激素(OR 5.71,95%CI 2.68-12.19)、甲氨蝶呤(OR 5.25,95%CI 2.01-13.74)和肿瘤坏死因子抑制剂(OR 2.32,95%CI 1.10-4.93)与PJP风险升高相关。

关键数值与推荐

  • 使用柳氮磺吡啶者PJP风险降低:未匹配调整OR 0.18(95%CI 0.00-0.92),匹配OR 0.08(95%CI 0.00-0.36)。
  • 未使用柳氮磺吡啶者中,肺部疾病OR 3.88(95%CI 1.89-7.95),糖皮质激素OR 5.71(95%CI 2.68-12.19),甲氨蝶呤OR 5.25(95%CI 2.01-13.74),肿瘤坏死因子抑制剂OR 2.32(95%CI 1.10-4.93)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出结果有待未来前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the prophylactic effect of sulfasalazine against Pneumocystis jirovecii pneumonia (PJP) among rheumatoid arthritis (RA) patients. METHODS: We used a nationwide Japanese multicenter RA database to extract data from 2005 and 2014. To identify PJP cases, we selected patients hospitalized for PJP and verified their diagnosis. Two control groups, one unmatched and the other matched for age, sex, glucocorticoid, methotrexate, and tacrolimus dosage, and the use (and type, if used) of biological disease-modifying antirheumatic drug were selected by incidence-density sampling. The odds ratios for PJP associated with sulfasalazine use and other clinical factors were estimated by exact and standard conditional logistic regression. RESULTS: From 18,668 participants, 60 cases, 356 unmatched controls, and 337 matched controls were selected. None of the cases received sulfasalazine before PJP onset. A comparison of the cases with the unmatched controls showed that sulfasalazine use carried a decreased risk of PJP (adjusted odds ratio 0.18, 95% confidence interval 0.00-0.92). A comparison of the cases and matched controls also showed that sulfasalazine use had a decreased risk of PJP (0.08, 0.00-0.36). In an analysis of the cases and unmatched controls who did not receive sulfasalazine, an increased risk of PJP was associated with lung disease (3.88, 1.89-7.95) and the use of glucocorticoid (5.71, 2.68-12.19), methotrexate (5.25, 2.01-13.74), and tumor necrosis factor inhibitors (2.32, 1.10-4.93). CONCLUSIONS: The results of this nested case-control study demonstrated the preventive effect of sulfasalazine against PJP. The results await confirmation by future prospective studies.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Nunokawa T, Yokogawa N, Shimada K, et al. Prophylactic effect of sulfasalazine against Pneumocystis pneumonia in patients with rheumatoid arthritis: A nested case-control study. Semin Arthritis Rheum. 2018. PMID: 30057321. doi:10.1016/j.semarthrit.2018.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。